Immune-Mediated Adverse Drug Reactions (IM-ARDs) in the Form of Drug-Induced Immune Thrombocytopenia and Cutaneous Adverse Drug Reactions (CARD) Due to Clindamycin in an Human Immunodeficieny Virus (HIV) Patient
American Journal of Case Reports · 2022
DOI: 10.12659/ajcr.938358 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Case Reports, 2022. Verfasst von Nata Pratama Hardjo Lugito und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia. Hauptthemen laut MEDLINE: HIV Infections, Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia, Purpura. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND Many drugs have been reported to cause immune-mediated adverse drug reactions (IM-ADRs) in human immunodeficiency virus (HIV) patients; the most common is cutaneous adverse drug reaction (CADR). Immune thrombocytopenia purpura (ITP) is frequent in HIV patients, and it can be caused HIV, opportunistic infections, or drugs. Although drugs can cause immune thrombocytopenia, termed drug-induced immune thrombocytopenia (DIIT), there has been no study on DIIT in HIV patients. CASE REPORT A 33-year-old male patient was admitted to our hospital with pruritic skin lesion over the entire body, which started 7 days before. He was diagnosed with HIV infection, brain toxoplasmosis, and pulmonary tuberculosis 2 weeks before admission, and was given trimethoprim sulphamethoxazole, isoniazid, rifampicin, pyrazinamide, and ethambutol. Clindamycin was added 10 days before admission. Skin examination revealed generalized erythematous macules with palpable petechiae and purpura. The platelet count was 141 000/µL when he was diagnosed with HIV, and it was 2000/µL at the time of admission. Clindamycin was discontinued and he was given steroids and platelet transfusion. The skin lesions improved along with an increased platelet count. He was discharged on the 10th day of admission, with platelet count of 42 000/µL. When he returned to the outpatient clinic on the 15th day, his platelet was 54 000/µL. The skin lesions had resolved completely and become hyperpigmented, and no purpura or petechiae were seen. CONCLUSIONS We present a case of an HIV patient with IM-ADR in the form of DIIT in conjunction with CADR that might have been caused by clindamycin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia.
- Department of Dermato-Venereology, Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia.
- Department of Pathological Anatomy, Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia.
ORCID-Profile: Nata Pratama Hardjo Lugito, Andree Kurniawan
Zitieren
APA
Hardjo Lugito, N. P., Kurniawan, A., Jayadi, N. N., & Kristiani, E. (2022). Immune-Mediated Adverse Drug Reactions (IM-ARDs) in the Form of Drug-Induced Immune Thrombocytopenia and Cutaneous Adverse Drug Reactions (CARD) Due to Clindamycin in an Human Immunodeficieny Virus (HIV) Patient. American Journal of Case Reports. https://doi.org/10.12659/ajcr.938358
Vancouver
Hardjo Lugito NP, Kurniawan A, Jayadi NN, Kristiani E. Immune-Mediated Adverse Drug Reactions (IM-ARDs) in the Form of Drug-Induced Immune Thrombocytopenia and Cutaneous Adverse Drug Reactions (CARD) Due to Clindamycin in an Human Immunodeficieny Virus (HIV) Patient. American Journal of Case Reports. 2022. doi:10.12659/ajcr.938358
BibTeX
@article{HardjoLugito2022,
author = {Hardjo Lugito, Nata Pratama and Kurniawan, Andree and Jayadi, Nana Novia and Kristiani, Erna},
title = {Immune-Mediated Adverse Drug Reactions (IM-ARDs) in the Form of Drug-Induced Immune Thrombocytopenia and Cutaneous Adverse Drug Reactions (CARD) Due to Clindamycin in an Human Immunodeficieny Virus (HIV) Patient},
journal = {American Journal of Case Reports},
year = {2022},
doi = {10.12659/ajcr.938358}
}
EUVIMED